Randomized, open-labelled study evaluating the antiviral efficacy, safety, and tolerability of continuing lamivudine therapy or switching to entecavir in subjects with chronic hepatitis B with detectable HBV [hepatitis B virus] DNA.

Trial Profile

Randomized, open-labelled study evaluating the antiviral efficacy, safety, and tolerability of continuing lamivudine therapy or switching to entecavir in subjects with chronic hepatitis B with detectable HBV [hepatitis B virus] DNA.

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Oct 2016

At a glance

  • Drugs Entecavir (Primary) ; Lamivudine (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Jan 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 19 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top